Arcutis Biotherapeutics, Inc. (ARQT)
Nasdaq · Common stock · Pharmaceutical Preparations
As of Oct 22, 12:30 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow ARQT in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on ARQT and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
ARQT at a glance
Key statistics
$4.01B
Market capitalization
- Previous close
- $31.87
- Open
- $31.94
- Day range
- $31.55 – $32.48
- Volume
- 693.1K
- Average volume (30 sessions)
- 3.22M
- Shares outstanding
- 125.69M
- Price / earnings
- 140.5
- Earnings per share
- $0.23
- Price / book
- 18.2
- Price / sales
- 8.6
- Beta (1 year, vs SPY)
- 1.05
Where the price sits in its year
52-week range
93% of the range
- Below the 52-week high
- -3.1%
- Above the 52-week low
- +67.3%
Completed sessions through Oct 21, 2026
Technical snapshot
Above its 50-day and 200-day averages
- 20-day average
- $27.08+17.7%
- 50-day average
- $25.86+23.2%
- 200-day average
- $25.12+26.9%
Between the conventional 30 and 70 bands.
+20.7%
1 week
+14.7%
1 month
+16.6%
3 months
+9.7%
Year to date
+52.6%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with ARQT
ARQT on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on ARQT.
See the plans →
Every planScreen names like ARQT
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on ARQT
Put ARQT on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on ARQT
See whether there is an open premium alert on ARQT, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
ARQT headlines
- Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026
GlobeNewswire Inc. · Oct 21, 2026
- Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
GlobeNewswire Inc. · Oct 9, 2026
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc. · Oct 2, 2026
- Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
GlobeNewswire Inc. · Sep 2, 2026
- Arcutis Expands Board of Directors with Appointment of Chris Peetz
GlobeNewswire Inc. · Jul 16, 2026
- FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
GlobeNewswire Inc. · Jun 29, 2026
- Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference
GlobeNewswire Inc. · May 26, 2026
- Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire Inc. · May 6, 2026
SEC Form 4, most recent first
Insider filings
Welgus Howard G.
−2.3K
Director · Option exercise
· Oct 15, 2026
Welgus Howard G.
+2.3K
Director · Option exercise
$19.45K · Oct 15, 2026
Welgus Howard G.
−822
Director · Option exercise
· Oct 15, 2026
Welgus Howard G.
+822
Director · Option exercise
$5.36K · Oct 15, 2026
Welgus Howard G.
+1.0K
Director · Option exercise
$7.65K · Oct 15, 2026
Welgus Howard G.
−1.0K
Director · Option exercise
· Oct 15, 2026
Welgus Howard G.
−4.7K
Director · Open-market sale
$127.33K · Oct 15, 2026
Matsuda Masaru
−3.7K
See Remarks · Open-market sale
$91.85K · Sep 16, 2026
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Pharmaceutical Preparations
- Headquarters
- Westlake Village, CA
- Employees
- 354
- Listed since
- Jan 31, 2020
- Website
- arcutis.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.